Bridging method of adjusted significance levels α' in the target region concerning superiority design for normal data distribution in MRCT

doi:10.12092/j.issn.1009-2501.2018.01.012

Abstract

Abstract:

AIM: To explore the feasibility to adjust the significance levels α' in the target region as the basis of data in normal distribution for the primary efficacy endpoint, the reasonable value of adjusted significance levels α' and reasonable proportions of sample size in target region，and to make a reference for new drug approvals of Multi-Regional Clinical Trial (MRCT) in target region. METHODS: By using Monte Carlo simulation, we studied the conditional false positive rate (CFPR) and conditional power (CP) changing with the proportions K of the sample size in target region by adopting different significance levels given that the treatment effect was shown to be significant under the significance level α=0.05 based on different sized MRCTs. RESULTS:Simulations results showed that CFPR and CP increased with the increasing significance level α' and the bigger K, the bigger CFPR. In addition, CFPR could be well controlled under 0.5 if K was no more than 30% and α' is no more than 0.5. Though f values 1.0, CP still kept low and was no more than 0.76 when K was no more than 15%. If f could be more than 0.8, CP would exceed 0.70 when K valued 20%. If f can be more than 0.8, CP will exceed 0.75 when K values 25%. When K valued 30%, CP would exceed 0.80 as long as f≥ 0.7. Lastly, even though f valued only 0.5, CP would exceed 0.80 when K valued 50%. CONCLUSION: The method in this study is easy to understand and operate, and have a better performance especially when f≥0.7.

Key words: conditional false positive rate, conditional power, multi-regional clinical trial, Monte Carlo simulation

CLC Number:

R969

SHANG Feng, YU Chengkai, YANG Peng. Bridging method of adjusted significance levels α' in the target region concerning superiority design for normal data distribution in MRCT[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 59-64.

References

［1］文宇, 赵明, 杨进波, 等. 对进口化学药品在国内进行临床研究的要求［J］. 中国临床药理学杂志, 2005, 21(3): 237-240.
［2］梁宇光, 刘泽源. 几个不同国家/地区药物临床研究监督检查工作现状及与中国模式的比较［J］. 中国药理通讯, 2010, 27(4): 42.
［3］蔡晶晶, 柏建岭, 陈峰, 等. 基于混合先验的MRCT中疗效一致性的评价［J］. 中国临床药理学与治疗学, 2016,21(2): 190-196.
［4］王菲, 谢海棠, 江波, 等. 多中心临床试验疗效一致性评价方法［J］. 中国临床药理学与治疗学, 2011, 16(10): 1126-1131.
［5］Liu J, Hsiao C, Hsueh H. Bayesian approach to evaluation of bridging studies［J］. J Biopharm Stat, 2002, 12(3): 401-408.
［6］刘泽宇, 周叙华, 韩孝先, 等. 新药临床试验中桥接试验的统计学相关相似性评价方法和桥接策略［J］. 中国新药杂志, 2016, 25(15): 1733-1736.
［7］Ministry of Health LAW. Basic Principles on Global Clinical Trials［EB/OL］. ［2007-9-28］.［2017-6-14］.http://www.pmda.go.jp/files/000153265.pdf.
［8］Chen X, Lu N, Nair R, et al. Decision rules and associated sample size planning for regional approval utilizing multiregional clinical trials［J］. J Biopharm Stat, 2012, 22(5):1001-1018.
［9］虞成凯, 王陵, 戚洋洋, 等. 基于α调整的国际多中心临床试验目标区二分类终点有效性研究的桥接方法［J］. 中国卫生统计, 2016, 33(1): 20-23.
［10］Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials［J］. Nat Rev Drug Discov, 2008, 7: 13-14.
［11］Misik V, Brady RV, Bolecek M, et al. Current trends in globalization of industry-sponsored clinical trials［J］. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 2014, 1(1):56-66.
［12］Karlberg JP. Globalization of sponsored clinical trials［J］. Nat Rev Drug Discov, 2008, 7(5): 458.
［13］林洁, 魏永越, 陈峰, 等. 中心效应及中心间样本不均衡对临床疗效评价的影响［J］. 中国临床药理学与治疗学, 2016, 17(4): 428-432.
［14］崔英子, 谢雁鸣, 杨海淼, 等. 探索性新药临床试验的回顾与展望［J］. 长春中医药大学学报, 2016, 32(5): 1046-1049.
［15］柳正植, 崔英子, 齐彩缤, 等. 多中心药物临床试验中牵头单位的职责［J］. 长春中医药大学学报, 2016, 32(4): 844-846.
［16］Quan H, Zhao PL, Zhang J, et al. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance［J］. Pharm Stat, 2010, 9(2): 100-112.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping. Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
[3]	WU Yonglei, WANG Dan, ZHANG Suiyang, WANG Ying, SUN Qin. Pharmacokinetics and pharmacodynamics of meropene administered by traditional prolonged infusion or optimized prolonged infusion in different tissues of septic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 767-774.
[4]	YE Long-qiang, SHI Lin-hui, QIU Xiao-hui, JIN Yu-hong, CAI Ting. Pharmacodynamics of prolonged dosing regimens of four β-lactam antibiotics against severe infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 51-55.
[5]	SHEN Hui-feng, ZHANG Sui-yang, CHANG Yan, REN Juan. Use of SAS iteration and Monte Carlo simulation to optimize use of Meropenem [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 529-535.
[6]	WANG Fei, XIE Hai-tang, JIANG Bo, YAN Fang-rong. Consistency efficacy assessment of multi-regional clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1126-1131.
[7]	YE Long-qiang, CAI Ting. Use of Monte Carlo simulation to optimize dosing regimens for Piperacillin-tazobactam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 901-905.
[8]	SHI Jun. Integration of pharmacokinetics and pharmacodynamics in antibiotic drug development and pharmacotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 121-133.
[9]	SHI Jun. Integretion of pharmacokinetics and pharmacodynamics in antibacterial drug development and pharmacotherap [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1099-1113.